Low vitamin d levels are common among patients undergoing orthopedic surgery. However, very little is known about how vitamin d affects outcomes in patients undergoing total joint replacement surgery. Our study will look at how common low vitamin d status is among patients undergoing total hip and total knee replacement surgery. We will also look at how vitamin d levels affect complication rates and hospital readmission rates.
Subjects are being asked to volunteer for this research study because your doctor feels that there is a significant probability that your sacroiliac joint (SIJ) contributes to your back pain and that you may be a candidate for sacroiliac surgery. If you meet the study requirements you will have a surgical procedure to have SImmetry devices implanted in your body.The SImmetry Sacroiliac Joint Fusion System is a device approved by the U.S. Food and Drug Administration (FDA).
This study will collect data to better understand pain reduction on your sacroiliac joint (low back/buttock) after implantation of the SImmetry Sacroiliac Joint Fusion device. Subjects will complete a total of 5 visits over the course of 2 years.
Patients who present with a native joint complaint and consent for the study will be tracked and their standard of care data will be monitored for outcomes of a septic joint. There are no additional actions taken outside of the standard of care. The results after the subject goal has been met will allow us to have a better understanding of the criteria for a septic joint.
PEPPER is a randomized study comparing the three most commonly used blood thinners in North America in patients who have elected to undergo primary or revision hip or knee joint replacement surgery. The blood thinners being compared are enteric coated aspirin plus air pump compression, low intensity warfarin, and rivaroxaban.
The purpose of this study is to collect and evaluate clinical and radiographic outcomes data on patients who have undergone, or will undergo, shoulder replacement surgery. Patients who receive a device from the Equinoxe® Shoulder System, manufactured and distributed by Exactech, Inc as well as patients who receive a device from another shoulder arthroplasty system may be included in this study.
The study will collect data to further affirm the safety and effectiveness of the Optetrak® Knee System product lines. Data will be collected in order to provide post-market subjective and objective evidednce of safety and effectivness. Data may be analyzed to support future presentation and publication of the Optetrak® Knee Systems and will be made available in the event Exactech is required to provide clinical evidence of the post market outcomes of the Optetrak Knee devices.
To collect data to further affirm the safety and effectiveness of the hip replacement systems manufactured and/or dustrubuted by Exactech, Inc. Data will be collected in order to provide post-market subjective and objective evidence of safety and effectivenss. Data may be analyzed to support future presentation and publication of theses systems and will be made available in the event Exactech is required to provide clinical evidence of the post market outcomes of the devices.
The Systemic Lupus Erythematosus (SLE) in Gullah Health, or SLEIGH, study is an observational study enrolling African Americans from the Sea Island communities of South Carolina and Georgia. We are enrolling patients, family members of patients, and unrelated community members. SLE is a potentially severe disease that can affect the entire body. SLE is more common in African Americans than Caucasians. The main purpose of this study is to find genes that, along with factors from the environment, result in the development of SLE. Volunteers in SLEIGH will be asked to answer questions about their health and have blood and urine collected for tests. After the first visit there may be one additional visit 2 or more years later. This is not a drug study.